AVEO Pharmaceuticals Inc. (AVEO)

1.98
0.01 0.50
NASDAQ : Health Technology
Prev Close 1.99
Open 1.98
Day Low/High 1.94 / 2.03
52 Wk Low/High 1.40 / 3.59
Volume 564.81K
Avg Volume 2.40M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 234.40M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

At some point, investors will give Aveo credit for tivozanib, says David Sobek.

3 Health Care Stocks Under $10 to Watch

3 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Bubble Fears Amid Relentless Market Climb

Bubble Fears Amid Relentless Market Climb

Strategists predict equity markets will be propelled higher with one warning of a bubble poised to be popped.

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock futures are looking to rebound from losses in the prior session.

Aveo, Delcath FDA Panel Live Blog

Aveo, Delcath FDA Panel Live Blog

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

Why Aveo's Tivozanib Should Win FDA Approval

Why Aveo's Tivozanib Should Win FDA Approval

Aveo's Tivozanib kidney cancer drug will get the nod from regulators.

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Ahead of Thursday's FDA panel, the agency asks if Aveo should conduct a second clinical trial.

Prepping for Aveo, Delcath FDA Panels

Prepping for Aveo, Delcath FDA Panels

It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer is keeping up with earnings all week and the unemployment numbers Friday.

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

A close examination of survival data from Aveo's phase III study raises concerns.

Biotech's Next Big Thing: Aveo

Biotech's Next Big Thing: Aveo

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc.

AVEO Oncology To Present At The 2013 RBC Capital Markets&#8217; Healthcare Conference

AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

New survival data from the phase III study of Aveo's tivozanib were released Tuesday night.

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 ( TIvozanib Versus s Orafenib in 1 st line...

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

New survival data on Aveo's tivozanib to be presented at a medical meeting next week.

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013.

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be ...

AVEO Announces Closing Of Public Offering

AVEO Announces Closing Of Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock.

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of...

TheStreet Quant Rating: D- (Sell)